This study examined whether zonisamide (ZNS) cotreatment delays dopamine transporter (DAT) reduction on SPECT in Parkinson disease (PD) patients. The study participants met the following criteria: (i) age ≥40 years; (ii) HY stage = 2 or 3; (iii) average specific binding ratio (SBR) ≥2.00; (iv) levodopa administration without a prior history of ZNS use before the first DAT-SPECT (baseline). Attending physicians initially determined whether ZNS (25 mg/day) should be used or not. Levodopa and other anti-PD medications were not restricted. The second DAT-SPECT (endpoint) was conducted 1.2 ± 0.2 years after the first DAT-SPECT. Clinicoradiological changes of HY stage, UPDRS parts II to IV, dyskinesia subscore, and SBR were calculated.
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Clinical Research
Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: a retrospective, observational cohort study DAT-SPECT can analyze the integrity of the nigrostriatal projection pathway [1] . This imaging is performed for a differential diagnosis of PD compared to essential tremor, vascular parkinsonism, and drug-induced parkinsonism [2] . Previous postmortem examinations have shown the significant correlation between striatal DAT bindings and substantia nigra cell counts in patients with dopaminergic neurodegeneration [3] .
A postmortem study suggested that striatal DAT bindings might reflect axonal dysfunction or DAT expression in PD patients [4] . Longitudinal studies of DAT-SPECT for therapeutic interventions have been reported [5] [6] [7] [8] . DAT-SPECT displayed dopamine reduction in asymptomatic G2019S-LRRK2 mutation carriers;
G2019S-LRRK2 mutation is known as a high risk factor for PD development [9] . An experimental study in an animal model of PD also suggested the relationship between DAT and striatal dopamine contents [10] . Therefore, DAT-SPECT is used as a possible biomarker for progressive evaluation of presynaptic dopaminergic dysfunction in the nigrostriatal pathway of PD patients.
Zonisamide (ZNS), 1,2-benzisoxazole-3-methanesulfonamide, has been used for more than 20 years as an anti-epileptic drug in Japan [11] . This drug also improves motor A C C E P T E D M A N U S C R I P T symptoms on the unified Parkinson's disease rating scale (UPDRS) part III in PD patients [12, 13] . In 2009, ZNS was approved as an anti-PD drug that was an adjunctive therapy for PD in Japan. ZNS monotherapy ameliorated motor and sleep dysfunction in de novo patients with early-stage PD [14] . Previous experimental studies also revealed that ZNS attenuated loss of dopaminergic neurons in animal models of PD [15] [16] [17] [18] . The clinical and experimental evidence prompted us to evaluate whether ZNS administration can delay progression of DAT reduction on DAT-SPECT in PD patients.
Materials and methods
Enrolled PD patients
All patients were recruited from the Department of Neurology, Toho University
Medical Center Omori Hospital, Tokyo, Japan. They were diagnosed according to the UKPD Society Brain Bank criteria [19] . All patients underwent the first DAT-SPECT (baseline) for further differential diagnosis before the entry into this study. The patients selected for the study fulfilled the following criteria: (i) No prior history of ZNS treatment before the first DAT-SPECT; (ii) age ≥ 40 years; (iii) levodopa administration and examination using the Hoehn and Yahr (HY) stage and UPDRS parts II-IV; (iv) HY stage = 2 or 3; and (v) average value of the right and left striatal specific binding ratio (SBR) on DAT-SPECT ≥ 2.00. Patients meeting the following criteria were excluded: concomitant use of selective serotonin reuptake inhibitors, severe degree of dementia, liver dysfunction, known allergy to iodine, and a prior history of serious cardiac disease. All patients participating in the study were informed of the purpose and the method of the present study, and they all provided written A C C E P T E D M A N U S C R I P T informed consent. The study was approved by the Review Board of the Toho University Medical Center Omori Hospital (M16003).
ZNS administration
Before initiation of the study, each attending physician freely selected medications of dopamine receptor agonists (DAs: rotigotine, pramipexole, and ropinirole), selegiline, entacapone, and/or ZNS for progression of motor symptoms and wearing off. During the study, the patients were divided into two groups: ZNS group and non-ZNS group.
According to ZNS approved usage and dose in Japan, the patients were initially administered the drug at a daily dose of 25 mg (per oral); the dose was increased to 50 mg/day if the higher dose was expected to improve wearing off during the study.
Concomitant use of levodopa and other anti-PD medications, including anticholinergics, amantadine, droxidopa, selegiline, entacapone, and DAs, were not restricted. Treatment with or without ZNS was continued for 1.2 ± 0.2 years after the first DAT-SPECT. Patients in the ZNS group who stopped taking ZNS or those in the non-ZNS group who started ZNS were withdrawn from the study.
Neurological evaluation
Neurological examination was performed every 1 or 2 months. The HY stage and UPDRS parts II-IV were evaluated on time at the baseline and at the endpoint (second DAT-SPECT) by each attending physician. The tremor score and the dyskinesia subscore were measured at the baseline and the endpoint. The tremor score was defined as the sum of UPDRS part II item 16 (self-report), part III item 20 (resting tremor), and part III item 21 (action/positional tremor) [20] . The dyskinesia subscore was defined as the sum of UPDRS part IV items 32-34. The interval between baseline A C C E P T E D M A N U S C R I P T and endpoint was 1.2 ± 0.2 years. Changes in UPDRS parts II-IV were calculated as endpoint score -baseline score. equipped with low-to-medium-energy general-purpose collimators. The data were reconstructed by filtered back-projection with a Butterworth filter (order = 8; cut-off = 0.5 cycles/cm) and corrected for attenuation by Chang's method with a uniform attenuation coefficient (0.08/cm). Scatter correction was performed using the triple-energy-window method including a main energy window (159 keV ± 10.5%) and two subwindows (7%).
DAT-SPECT
The striatal SBR was calculated semiquantitatively using DAT VIEW automated analysis software (Nihon Medi-Physics, Tokyo, Japan) based on Tossici-Bolt's method in which the region of interest was placed automatically [21] . As mentioned before, the second DAT-SPECT (endpoint) was conducted 1.2 ± 0.2 years after the first imaging (baseline). The following formulas were used: SBR change = Baseline SBR -Endpoint SBR. Change rate of SBR = (SBR change/Baseline SBR) × 100 (%). To assess the asymmetric degree of the striatal SBR, a striatal asymmetry index (SAI) was calculated as follows [22] :
For this study, the normal range of the SBR value was obtained in 10 age-matched control subjects who had neither PD symptoms nor abnormal neurological examination.
The SBR range was 4.83-6.61 in controls. The baseline SBR on the first DAT-SPECT ≥ 2.00 at inclusion criteria was determined as 60% or less reduction of the mean SBR
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Statistical analysis
All data were shown as the mean (standard deviation [SD] ). The differences of clinical and SBR data at the baseline or endpoint between the ZNS group and non-ZNS groups were analyzed by unpaired Student's t-test. The differences of clinical and SBR data between baseline and endpoint within each group were analyzed by paired Student's t-test. The differences of clinicoradiological variables between the ZNS group and non-ZNS groups were analyzed by a two-way repeated-measures analysis of variance (ANOVA). Multiple logistic regression analysis was performed to identify an independent preventive factor for SBR reduction. P value of < 0.05 was considered statistically significant. Statistical analyses were performed using PASW Statistics 18.0 (IBM, Chicago, IL, the USA). Table 1 lists the demographic data of the patients. The baseline data of age, sex, disease duration, and HY stage did not differ statistically between the ZNS and non-ZNS groups. In addition, there were no significant differences in UPDRS parts II-IV, tremor scores, and dyskinesia subscores at the baseline between the ZNS and non-ZNS groups. The mean dose (SD) of levodopa was 277 (155) mg/day in the ZNS group and 290 (114) mg/day in the non-ZNS group. In each group, 3 patients were administered selegiline or entacapone. DAs (rotigotine, pramipexole, and ropinirole)
Results
Demographic data of participating patients at the baseline
were administered to 12 patients in the ZNS group and 11 patients in the non-ZNS group, and 1 patient in each group was given istradefilline. Daily doses of levodopa and other anti-PD medications did not differ significantly between the ZNS and
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non-ZNS groups.
HY stage, UPDRS parts II-IV, tremor score, dyskinesia subscore and anti-PD medications at the endpoint
In both groups, the range and mean (SD) of the interval between the first and second DAT-SPECT were 1.0-1.2 years and 1.0 (0.1) year, respectively. Table 2 lists the HY stage, UPDRS parts I-IV, tremor score, and dyskinesia subscore at the endpoint.
Changes in the HY stage, UPDRS parts I-IV, and tremor score from baseline to endpoint did not differ significantly between the ZNS and non-ZNS groups. Otherwise, the mean (SD) of the dyskinesia subscore was 0.1 (0.3) in the ZNS group and 1.0 (0.5)
in the non-ZNS group. The frequency of dyskinesia development was significantly lower in the ZNS group compared to the non-ZNS group (P < 0.01). Daily doses of levodopa at the endpoint did not differ significantly between both groups. Additional treatment with other anti-PD medications was necessary due to progression of motor deficits and worsening of wearing off in the non-ZNS group. The number of selegiline (n = 1), entacapone (n = 9), or DA (n = 4) users increased in the non-ZNS group; however, these medications were not administered to the ZNS group during the study.
In the ZNS group, 3 patients (20%) did not take DAs, while all patients in the non-ZNS group took DAs (Table 2) . With regard to adverse effects at the endpoint, 2 patients in each group experienced mild daytime sleepiness; these 4 patients had been co-administered DAs. There was no significant difference in sleepiness between both groups. Table 3 summarizes the DAT-SPECT data. The SBR decreased significantly at the endpoint in the non-ZNS group compared to the baseline (P < 0.001), but did not differ ACCEPTED MANUSCRIPT
DAT-SPECT findings at the baseline and endpoint
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statistically between baseline and endpoint in the ZNS group (Fig. 1) . The SBR decline rate decreased significantly in the ZNS group compared to the non-ZNS group (P < 0.01). There was a significant association between the SBR change and ZNS treatment by multiple logistic analysis. The odds ratio (OR) was adjusted by clinical variables, including age, HY stage, UPDRS parts II-IV, and use of anti-PD medications. ZNS co-administration was an independent preventive factor for SBR reduction (OR = 0.913; 95% confidence interval [CI] = 0.847-0.984; P = 0.0168). There were no significant differences between the baseline and endpoint SAI in either group.
Discussion
The present study examined whether ZNS co-administration can delay DAT dysfunction in the nigrostriatal pathway. ZNS delayed SBR reduction on DAT-SPECT in relatively early-stage PD patients. Motor deficits on the HY stage and UPDRS parts II-IV scores did not differ significantly between patients treated with and without ZNS.
However, additional medications such as selegiline, entacapone, and/or DAs (rotigotine, pramipexole, and ropinirole) were required due to progression of motor deficits and deterioration of wearing off in the non-ZNS group. These anti-PD medications were not administered to the ZNS group during the study. The dyskinesia subscore was significantly lower in the ZNS group compared to the non-ZNS group.
These symptomatic benefits revealed that ZNS adjunctive therapy improved wearing off and inhibited development of dyskinesia.
Although the pharmacological mechanism of ZNS has not been elucidated fully, the following effects have been revealed: activation of dopamine synthesis, suppression of monoamine oxidase (MAO) type B, prevention of dopamine quinone formation,
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blockage of T-type calcium currents, and potentiation of sodium channel inactivation [15, [23] [24] [25] [26] [27] . ZNS attenuates loss of dopaminergic neurons in animal models of PD.
Neuroprotective effects of this drug have also been tested against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in mice [16, 17] . ZNS suppressed -synuclein-triggered neurotoxicity in a rat model of familial PD [18] . In another animal model of PD, rotenone inhibited the mitochondrial complex I [28] . Chronic treatment with rotenone caused nigrostriatal dopaminergic degeneration and formation of ubiquitin-and -synuclein-positive nigral inclusions, leading to motor deficits in rats [29] . ZNS treatment rescued striatal neurons from complex I mitochondrial dysfunction by rotenone. The efficacy was blocked by the administration of bicucculine, competitive antagonist of gamma-amino butyric acid (GABA) A receptors. These results indicated that the neuroprotective mechanism of ZNS against rotenone might contribute to potentiation of GABA-mediated inhibition via activation of GABA A receptors [30] .
Besides animal PD models, the therapeutic potential of ZNS has been reported in various models of neurological diseases or neuronal injury [31] [32] [33] [34] . ZNS protected spinal motor neurons in wobbler mouse motor neuron disease [32] and mouse embryo primary culture [33] . It induced messenger RNA expression of brain-derived neurotrophic factor, nerve growth factor, neurotrophin-4/5, and tropomyosin receptor kinase A and B [33] . ZNS treatment decreased motor dysfunction and denervation muscle atrophy [32, 33] . In addition, the ZNS-loaded micelles promoted motor function recovery and enhanced neuron and axon densities in a rat spinal cord injury model [34] .
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With regard to antioxidative action, ZNS scavenges free radicals of hydroxyl and nitric oxide [35] and can suppress nitric oxide synthase activity [36] and lipid peroxide formation [37] . 8-hydroxy-20-deoxyguanosine (8-OHdG) is a biomarker for oxidative stress, and urinary 8-OHdG levels were decreased in ZNS-treated PD patients [38] .
These previous studies revealed that ZNS is a multifunctional and neuroprotective drug for several kinds of neuronal diseases [15-18, 23-27, 30-38] .
Our study showed that ZNS administration slows striatal SBR reduction on DAT-SPECT in relatively early-stage PD patients. Several studies have reported DAT alternations after anti-PD medications [5, [39] [40] [41] . Two previous studies have described whether selegiline treatment influences DAT in PD patients [39] and adult rats [40] . In the former study, striatal DAT levels on DAT-SPECT did not alter significantly at 33 ± 5 days after selegiline (10 mg/day) treatment in PD patients compared to the baseline and withdrawal [39] . One experimental study reported the effect of selegiline on striatal DAT expression in adult Sprague-Dawley rats. On 1 day and 21 days after subcutaneous administration of selegiline (0.25 mg/kg), striatal DAT levels, which were measured by immunoblotting assay, were increased significantly [40] . With regard to DAs, compared to levodopa treatment, initial treatment with pramipexole decelerated progression of DAT reduction on SPECT in early-stage PD [5] . Rotigotine monotherapy up-regulated FP-CIT uptake in de novo PD patients: FP-CIT uptake increased by 13% in the caudate nucleus and 17% in the putamen at 12 weeks after the optimal dose treatment [41] . At the endpoint in our study, selegiline was administered to 4 patients (1 and 3 patients in the ZNS and non-ZNS groups, respectively), pramipexole was given to 5 patients (2 and 3 patients in the ZNS and non-ZNS groups, respectively), and rotigotine was administered to 20 patients (10 patients each in the ACCEPTED MANUSCRIPT
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. Because the number of selegiline, pramipexole or rotigotine users was almost equal in both groups, these medications did not seem to reflect SBR changes significantly. Also, there were no significant changes in the SBR between our patients treated with and without rotigotine. We suspected that different clinical and therapeutic profiles of rotigotine users might lead to inconsistent results between the present and previous DAT-SPECT studies [41] .
Besides pharmacological effects on DAT, motor deficit progression is slower in tremor-dominant PD patients compared to non-tremor-dominant patients. This slower rate of progression in tremor-dominant PD was associated with less severity of nigral cell loss on postmortem examination [42] . A previous DAT-SPECT study disclosed a higher SBR of the caudate nucleus in tremor-dominant PD patients than that in non-tremor-dominant PD patients [43] . Our study showed no significant differences in tremor scores between the ZNS group and non-ZNS groups. Tremor degrees could not influence the striatal SBR in our patients.
With regard to therapeutic evaluation at the endpoint, additional uses of selegiline, entacapone, and/or DAs were needed to improve motor deficits and wearing off in the non-ZNS group. These anti-PD medications were not required newly in the ZNS group.
Dyskinesia developed less frequently in ZNS-treated patients. These results indicated that ZNS has a therapeutic benefit by attenuating wearing off and suppressing the development of dyskinesia. A previous 123 I-FP-CIT positron emission tomography study reported that a decrease in putaminal DAT activities played a role in the levodopa-induced dyskinesia in de novo PD patients [44] . Preservation of striatal DAT expression may contribute to a low frequency of dyskinesia and wearing off in ZNS-treated patients.
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Conclusions
The present study indicated that ZNS treatment depressed striatal SBR reduction in patients with relatively early-stage PD. This medication also ameliorated wearing off and inhibited the development of dyskinesia during this study. These clinicoradiological results suggested a promising potential that ZNS co-administration could delay presynaptic denervation of the nigrostriatal pathway, leading to slower disease progression in PD patients.
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A C C E P T E D M A N U S C R I P T Table 2 . Clinical changes of the HY stage, UPDRS parts II-IV, and anti-PD medication at the endpoint Data expressed as the mean (SD).
Range of interval time between the baseline and endpoint of the study. A C C E P T E D M A N U S C R I P T 
Data expressed as the mean (SD).
Range of interval time between the first and second DAT imaging.
DAT-SPECT, dopamine transporter-single-photon emission computed tomography; SAI, striatal asymmetry index; SBR, specific binding ratio; ZNS, zonisamide.
*P < 0.001 between baseline and endpoint in the non-ZNS group by paired Student's t-test. † P < 0.01 between the ZNS and non-ZNS groups by two-way repeated-measures ANOVA. § ZNS co-administration was an independent preventive factor for SBR reduction by multiple logistic analysis (OR = 0.913; 95% CI = 0.847-0.984; P = 0.0168).
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